- ￥6768
- AntibodySystem
- 0.31-5 μg/mL
- 0.156 μg/ml
- KDC90703
- France
- 2025年07月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
999
- 供应商：
AntibodySystem
- 检测范围：
0.31-5 μg/mL
- 检测方法：
Colorimetric
- 应用：
ELISA
- 标记物：
HRP
- 样本：
Plasma, Serum
- 灵敏度：
0.156 μg/ml
- 规格：
96T
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 检测方法 | Colorimetric |
| 精准度 |
CV<20% |
| 样本类型 | Plasma, Serum |
| 实验类型 | Quantitative |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 背景 | Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies. |
| 别名 | GEN3013, CAS: 2134641-34-0 |
| 运输 | 2-8 ℃ |
| 备注 | For Research Use Only. |
AntibodySystem Laboratories SAS was established in 2019 in France as an independent brand entity focused on the research, development, and production of protein and antibody reagents in the life sciences field. Our mission is to provide high-quality protein and antibody products to life science researchers worldwide. AntibodySystem's extensive product range includes traditional polyclonal antibodies, classic housekeeping antibodies, tag antibodies, high-activity proteins, in vivo functional antibodies, low-background flow cytometry antibodies, high-specificity nanobodies, specialized small molecule antibodies, premium phospho-specific antibodies, DNA/RNA antibodies, PEG antibodies, and more—spanning over ten product series.
Currently, AntibodySystem's product lines cover multiple research areas, including 48 types of viruses and superbugs, parasites, tumors, Alzheimer's disease, Parkinson's disease, hypersensitivity and allergic reactions, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
